Sante Capital Fund’s Inovio Pharmaceuticals INO Stock Holding History

Sante Capital Fund’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9,636	Closed	-$1.07M	–	69
2021 Q2	$1.07M	Buy	+9,636	New	+$926K	0.44%	59

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Sante Capital Fund's INO Position: Q3 2021 in Review

Sante Capital Fund sold out of Inovio Pharmaceuticals (INO) in Q3 2021, closing a stake of 9,636 shares — an estimated $1.07M sold.

Sante Capital Fund first reported a position in INO in Q2 2021 and held it in 1 quarter. The position peaked at $1.07M in Q2 2021. 213 funds tracked by Wall St. Rank hold INO as of Q3 2021.

Sante Capital Fund reported no remaining Inovio Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Sante Capital Fund sold 9,636 Inovio Pharmaceuticals shares in Q3 2021, an estimated $1.07M.
Sante Capital Fund first reported a position in Inovio Pharmaceuticals in Q2 2021 and held it in 1 quarter.
Sante Capital Fund's Inovio Pharmaceuticals position peaked at $1.07M in Q2 2021.
213 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2021.

Based on Sante Capital Fund's 13F filing for Q3 2021, filed 15 Nov 2021.